Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary D Chamberlin

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
JCO Global Oncology|March 10, 2020
Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified GuidelineE Gabriela Chiorean, Govind Nandakumar, Temidayo Fadelu, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylationSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Cancer Research|January 8, 2025
Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast CancerSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Breast Cancer Research and Treatment|June 21, 2020
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancerMary D Chamberlin, Jason D Wells, Kevin Shee, et al.
The Oncologist|July 25, 2015
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical CenterLaura J Tafe, Ivan P Gorlov, Francine B de Abreu, et al.
JAMA Network Open|March 22, 2024
Telephone-Based Rehabilitation Intervention to Optimize Activity Participation After Breast Cancer: A Randomized Clinical TrialKathleen Doyle Lyons, Stephen B Wechsler, Deborah B Ejem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
JCO Global Oncology|March 10, 2020
Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified GuidelineE Gabriela Chiorean, Govind Nandakumar, Temidayo Fadelu, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylationSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Cancer Research|January 8, 2025
Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast CancerSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Breast Cancer Research and Treatment|June 21, 2020
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancerMary D Chamberlin, Jason D Wells, Kevin Shee, et al.
The Oncologist|July 25, 2015
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical CenterLaura J Tafe, Ivan P Gorlov, Francine B de Abreu, et al.
JAMA Network Open|March 22, 2024
Telephone-Based Rehabilitation Intervention to Optimize Activity Participation After Breast Cancer: A Randomized Clinical TrialKathleen Doyle Lyons, Stephen B Wechsler, Deborah B Ejem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
Pageof 3